NCT05330208终止1 期
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects
Beijing Suncadia Pharmaceuticals Co., Ltd1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年5月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Incidence of hypoglycemic events
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1816 after single and multiple injection with different dose regimens in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and infertility females aged between 18 years and 55 years at screening.
- •Male subjects weight ≥50kg, female subjects weight ≥45kg. Body mass index (BMI) in the range of 19-26kg /m
- •HbA1c<6.2% at screening.
- •FPG>3.9mmol/L (70mg/dL) and <6.1mmol/L (110mg/dL) at screening
- •Agree to take effective contraceptive methods.
- •Able and willing to provide a written informed consent.
排除标准
- •The following clinical laboratory tests or examination abnormalities exist during the screening period:
- •Any clinically significant lab tests abnormal with one-time retest. 2) ALT and AST were higher than the upper limit of normal value. 3) Subject who has fatty liver disease diagnosed by ultrasound examination. 4) Subject who has abnormal thyroid function. 5) The 12-lead electrocardiogram (ECG) is abnormal and clinically significant, or shows QTcF>450 ms in male and 470 ms in female.
- •Positive infectious diseases screening tests: HBsAg, HCV-Ab, TP-Ig G, HIV-Ab
- •Having any of the following diseases or history:
- •Subject with a history of hypertension or with abnormal vital signs and clinical significance.
- •Subject with a history of life-threatening diseases within the previous 5 years prior to screening.
- •Subject with severe systemic infectious diseases within 1 month prior to screening.
- •Subject with medical history or family history of medullary thyroid cancer, multiple endocrine adenomatosis type 2, and previous history of pancreatitis.
- •Subject with major medical history of heart, liver, kidney, endocrine, digestive, blood, respiratory and genitourinary system or existing diseases of the above systems.
- •Use of any other medicine or other non-drug operations:
- •Prescription drugs, non-prescription drugs, food supplements, vitamins and Chinese herbal medicines within 2 weeks before administration.
- •Subject who received bariatric surgery or procedures, or use of weight-reducing drugs within 3 months prior to administration, or body weight change of more than ±10% within 3 months prior to administration.
- •Drugs that may affect glucose metabolism were used within 1 month before administration.
- •Subject who undergone other gastrointestinal surgery that could lead to malabsorption, or long-term use of drugs that had a direct impact on gastrointestinal motility prior to screening.
- •Any of the following conditions exists:
- •History of allergy to the study drug or any component of it.
- •Treatment with an investigational drug or device within 3 months (or 5 half-lives, whichever is longer) prior to screening.
- •History of regular alcohol consumption in the past week exceeding an average 15g per day and positive alcohol test.
- •More than 5 cigarettes per day or cigarettes in 48 hours before treatment and positive nicotine test.
- •Long time or in 48 hours before treatment drinking for tea, cola, coffee or any other soft drinking within 48 hours.
- •Strenuous exercise in 48 hours before treatment.
- •Subject with known or suspected history of drug abuse or positive urine drug screening test during screening.
- •Unwillingness to comply with lifestyle requirements during the trial.
- •Donate blood within 1 month before screening, or screening trauma or major surgical operation patients who donated blood ≥400 mL or lost blood ≥400 mL within 3 months before the screening.
- •Mentally incapacitated or language impaired subject cannot fully understand or participate in the test process.
- •The investigator assessed the subject's poor compliance or inability to draw blood due to arm vein conditions, or history of needle and blood sickness.
- •Other conditions or laboratory abnormality that may affect trial evaluations associated with study participation reviewed by the investigators.
研究组 & 干预措施
Group A
Experimental
干预措施: SHR-1816 (Drug)
Group B
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence of hypoglycemic events
时间窗: Day1 to Day8/Day29
Incidence of reaction of the injection sites
时间窗: Day1 to Day8/Day29
Number of adverse Events
时间窗: Day-2 to Day29/Day50
次要结局
- Pharmacodynamic (PD) profile of doses of SHR-1816 - fructosamine(Day-1 to Day15/Day29)
- Pharmacokinetic (PK) profile of SHR-1816 - AUC0-t(pre-dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336 hours post-dose)
- Pharmacokinetic (PK) profile of SHR-1816 - CL/F(pre-dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336 hours post-dose)
- Pharmacokinetic (PK) profile of SHR-1816 - MRTinf(pre-dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336 hours post-dose)
- Pharmacodynamic (PD) profile of doses of SHR-1816 - C-peptide(Day-1 to Day15/Day29)
- Pharmacokinetic (PK) profile of SHR-1816 - Cmax(pre-dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336 hours post-dose)
- Pharmacokinetic (PK) profile of SHR-1816 - Vz/F(pre-dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336 hours post-dose)
- Pharmacodynamic (PD) profile of doses of SHR-1816 - fasting blood glucose(Day-1 to Day15/Day29)
- Pharmacodynamic (PD) profile of doses of SHR-1816 - active GLP-1(Day-1 to Day15/Day29)
- Pharmacokinetic (PK) profile of SHR-1816 - AUC0-inf(pre-dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336 hours post-dose)
- Pharmacokinetic (PK) profile of SHR-1816 - Tmax(pre-dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336 hours post-dose)
- Pharmacokinetic (PK) profile of SHR-1816 - t1/2(pre-dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336 hours post-dose)
- Pharmacodynamic (PD) profile of doses of SHR-1816 - insulin(Day-1 to Day15/Day29)
- Pharmacodynamic (PD) profile of doses of SHR-1816 - glucagon(Day-1 to Day15/Day29)
- Pharmacodynamic (PD) profile of doses of SHR-1816 - total GLP-1(Day-1 to Day15/Day29)
- PD profile of multiple doses of SHR-1816 - HbA1c(Day-1, Day29)
- PD profile of multiple doses of SHR-1816 - weight(Day-1 to Day15/Day29)
- Immunogenicity(Day1 to Day29/Day50)
- PD profile of multiple doses of SHR-1816 - 7-points glucose profile(Day-1 to Day15/Day29)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy SubjectsHealthy VolunteersNCT02934269Celgene40
已完成
1 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult SubjectsLassa Virus InfectionHealthy Adult ParticipantsNCT05735249Arisan Therapeutics, Inc.94
已完成
1 期
A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly ParticipantsHealthyNCT06391827Dong-A ST Co., Ltd.90
已完成
1 期
A Study of Subcutaneous DR-01 in Healthy VolunteersHealthy VolunteerNCT06766864Dren Bio32
已完成
1 期
Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney DiseaseChronic Kidney DiseasesInterstitial Lung DiseaseNCT05914909AdAlta Limited8